Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.77 |
| ▸ | KDR | P35968 | 5/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.75 |
| ▸ | GAA | P10253 | 2/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | TP53 | P04637 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | CASP3 | P42574 | 1/20 | 0.66 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.66 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.66 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | TNKS | O95271 | 2/20 | 0.64 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29911198 | 1.00 | HDAC6 (0.77) | HDAC6KDRL3MBTL1GAATDP1 | |
| SCHEMBL19631488 | 0.87 | HDAC6 (1.00) | HDAC6KDRL3MBTL1GAATDP1 | |
| SCHEMBL15270551 | 0.87 | HDAC6 (0.79) | HDAC6KDRL3MBTL1GAATDP1 | |
| SCHEMBL29647754 | 0.87 | HDAC6 (1.00) | HDAC6KDRL3MBTL1GAATDP1 | |
| SCHEMBL6260903 | 0.87 | KDR (1.00) | HDAC6KDRL3MBTL1GAATDP1 | |
| SCHEMBL29434873 | 0.87 | KDR (1.00) | HDAC6KDRL3MBTL1GAATDP1 | |
| SCHEMBL19422867 | 0.86 | KDR (0.72) | HDAC6KDRL3MBTL1GAATDP1 | |
| SCHEMBL19748451 | 0.86 | HDAC6 (0.73) | HDAC6KDRL3MBTL1GAATDP1 | |
| SCHEMBL29911021 | 0.86 | KDR (0.72) | HDAC6KDRL3MBTL1GAATDP1 | |
| SCHEMBL29655108 | 0.86 | HDAC6 (0.73) | HDAC6KDRL3MBTL1GAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016793-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2024-01-18 | — | — | US | disclosed |
| US-11827626-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| EP-4037685-B1 | QUINOLINE THAT MODULATE SERCA AND ITS USE FOR TREATING DISEASE | NEURODON CORP (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230285382-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2023-09-14 | — | — | US | disclosed |
| CN-116744928-A | Quinolines modulating SERCA and their use for treating diseases | 神经元公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11730729-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| CN-113336784-B | 3-substituted benzofluorenone or 3-substituted naphthofluorenone derivatives and synthesis method thereof | 上海大学 | 2022-11-18 | — | — | CN | disclosed |
| US-20220016108-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2022-01-20 | — | — | US | disclosed |
| CN-113336784-A | 3-substituted benzofluorenone or 3-substituted naphthofluorenone derivatives and synthesis method thereof | 上海大学 | 2021-09-03 | — | — | CN | disclosed |
| CN-111575731-B | Method for electrochemically synthesizing C5 and C7 dihalogenated quinoline amide derivatives | 浙江工业大学 | 2021-08-24 | — | — | CN | disclosed |
| US-10772881-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION | 2020-09-15 | — | — | US | disclosed |
| CN-111575731-A | Method for electrochemically synthesizing C5 and C7 dihalogenated quinoline amide derivatives | 浙江工业大学 | 2020-08-25 | — | — | CN | disclosed |
| CN-109320497-B | Method for preparing phenanthridinone compound by copper compound induction | 广州大学 | 2020-07-31 | — | — | CN | disclosed |
| CN-106938985-B | 5-site alkenylated 8-acylaminoquinoline compound and one-pot preparation method thereof | 湖南大学 | 2020-05-05 | — | — | CN | disclosed |
| CN-107698586-B | Method for preparing pyridoquinazolinone compound by catalysis of copper compound | 广州大学 | 2020-02-07 | — | — | CN | disclosed |
| US-20190151303-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2019-05-23 | — | — | US | disclosed |
| CN-109320497-A | A method of phenanthridines ketone compounds are prepared by copper compound induction | 广州大学 | 2019-02-12 | — | — | CN | disclosed |
| CN-107698586-A | It is a kind of that the method for preparing Pyridine-quinazolinocompound compound is catalyzed by copper compound | 广州大学 | 2018-02-16 | — | — | CN | disclosed |
| US-20170281611-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | EIGER BIOPHARMACEUTICALS, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| WO-2016032569-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | CELLADON CORPORATION (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285382-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | HDAC6 1539/4885KDR 4506/4885L3MBTL1 4692/4885 |
| US-20170281611-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | ATP2A1, ATP2A3, ATP2A2 | HDAC6 611/4885KDR 4844/4885L3MBTL1 3273/4885 |
| US-10772881-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | HDAC6 1841/4885KDR 4683/4885L3MBTL1 4561/4885 |
| US-11730729-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | HDAC6 1539/4885KDR 4506/4885L3MBTL1 4692/4885 |
| US-11827626-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | HDAC6 1539/4885KDR 4506/4885L3MBTL1 4692/4885 |
| US-20190151303-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | HDAC6 1841/4885KDR 4683/4885L3MBTL1 4561/4885 |
| US-20220016108-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | HDAC6 1539/4885KDR 4506/4885L3MBTL1 4692/4885 |
| US-20240016793-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | HDAC6 1539/4885KDR 4506/4885L3MBTL1 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.